相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology
Maria Del Carmen Rodriguez Pena et al.
VIRCHOWS ARCHIV (2020)
Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors
Tuan Zea Tan et al.
EUROPEAN UROLOGY (2019)
A phase Ill, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guerin (BCG) versus BCG alone in high-risk, BCG-naive non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC).
Maria De Santis et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer
Ana Blanca et al.
APMIS (2019)
被撤回的出版物: lncRNA PEG10 promotes cell survival, invasion and migration by sponging miR-134 in human bladder cancer (Retracted article. See vol. 145, 2022)
Fuquan Jiang et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer
Emanuela Trenti et al.
CANCER CYTOPATHOLOGY (2019)
Management of metastatic bladder cancer
Rosa Nadal et al.
CANCER TREATMENT REVIEWS (2019)
lncRNA TUC338 is a potential diagnostic biomarker for bladder cancer
Gang Li et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
MiR-101 acts as a novel bio-marker in the diagnosis of bladder carcinoma
Xiaoyan Chen
MEDICINE (2019)
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-2019 Update
Marko Babjuk et al.
EUROPEAN UROLOGY (2019)
Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer
Ricardo Leao et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
DNA hypermethylation within TERT promoter upregulates TERT expression in cancer
Donghyun D. Lee et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Measurement of Urinary Level of a Specific Competing endogenous RNA network (FOS and RCAN mRNA/ miR-324-5p, miR-4738-3p, /lncRNA miR-497-HG) Enables Diagnosis of Bladder Cancer
Sanaa Eissa et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2019)
Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study
Rui Batista et al.
FRONTIERS IN GENETICS (2019)
Urovysion FISH Could Be Effective and Useful Method to Confirm the Identity of Cultured Circulating Tumor Cells from Bladder Cancer Patients
Tae-Jung Kim et al.
JOURNAL OF CANCER (2019)
The effects of cigarette smoking extracts on cell cycle and tumor spread: novel evidence
Aldo Pezzuto et al.
FUTURE SCIENCE OA (2019)
Grading of Urothelial Carcinoma and The New World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016
Eva M. Comperat et al.
EUROPEAN UROLOGY FOCUS (2019)
Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients
Judith Bosschieter et al.
EUROPEAN UROLOGY (2018)
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence SWOG S0337 Randomized Clinical Trial
Edward M. Messing et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Evaluation of Urinary DNA Methylation as a Marker for Recurrent Bladder Cancer: A 2-Center Prospective Study
Tetsuya Shindo et al.
UROLOGY (2018)
An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer
Francesco Soria et al.
WORLD JOURNAL OF UROLOGY (2018)
Short-term benefit of smoking cessation along with glycopirronium on lung function and respiratory symptoms in mild COPD patients: a retrospective study
Aldo Pezzuto et al.
JOURNAL OF BREATH RESEARCH (2018)
Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy
Simeon U. Springer et al.
ELIFE (2018)
Association of Cigarette, Cigar, and Pipe Use With Mortality Risk in the US Population
Carol H. Christensen et al.
JAMA INTERNAL MEDICINE (2018)
Extracellular Vesicles in Bladder Cancer: Biomarkers and Beyond
Yu-Ru Liu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Current Use and Promise of Urinary Markers for Urothelial Cancer
William Tabayoyong et al.
CURRENT UROLOGY REPORTS (2018)
Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial
J. Alfred Witjes et al.
EUROPEAN UROLOGY ONCOLOGY (2018)
Forward and reverse mutations in stages of cancer development
Taobo Hu et al.
HUMAN GENOMICS (2018)
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients
Irene Resch et al.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2018)
Systemic, perioperative management of muscle-invasive bladder cancer and future horizons
Samuel A. Funt et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets
Eugene J. Pietzak et al.
EUROPEAN UROLOGY (2017)
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
Marko Babjuk et al.
EUROPEAN UROLOGY (2017)
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
J. Alfred Witjes et al.
EUROPEAN UROLOGY (2017)
Validation of a mRNA-based urine test for bladder cancer detection in patients with hematuria
F.J.P. Van Valenberg et al.
EUROPEAN UROLOGY SUPPLEMENTS (2017)
ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence
Mathieu F. Chevalier et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications
Stephanie A. M. Wankowicz et al.
JOURNAL OF UROLOGY (2017)
The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies
Zheng Zhang et al.
ONCOTARGET (2017)
An integrated double-filtration microfluidic device for isolation, enrichment and quantification of urinary extracellular vesicles for detection of bladder cancer
Li-Guo Liang et al.
SCIENTIFIC REPORTS (2017)
Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine
Francoise Descotes et al.
BRITISH JOURNAL OF CANCER (2017)
A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection
Hugh J. Lavery et al.
BMC CANCER (2017)
Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer
Zhenqiang Fang et al.
TUMOR BIOLOGY (2016)
Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications
Boaz Kurtis et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2016)
Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guerin
Ashish M. Kamat et al.
EUROPEAN UROLOGY (2016)
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours
Peter A. Humphrey et al.
EUROPEAN UROLOGY (2016)
Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement
Matthew I. Milowsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations
Wassim Kassouf et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2016)
Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project
Claudia Schmitz-Draeger et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2016)
ImmunoCyt test compared to cytology in the diagnosis of bladder cancer: A meta-analysis
Houguang He et al.
ONCOLOGY LETTERS (2016)
Massive interstitial copy-neutral loss-of-heterozygosity as evidence for cancer being a disease of the DNA-damage response
Yogesh Kumar et al.
BMC MEDICAL GENOMICS (2015)
Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature
Luis A. Kluth et al.
EUROPEAN UROLOGY (2015)
Molecular Biology of Bladder Cancer
William Martin-Doyle et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2015)
Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer
Ismail Hosen et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer
Xin Zhang et al.
Oncotarget (2015)
Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer
Xiumei Jiang et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Margaret A. Knowles et al.
NATURE REVIEWS CANCER (2015)
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2014)
Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
Woonyoung Choi et al.
CANCER CELL (2014)
Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome
Yves Allory et al.
EUROPEAN UROLOGY (2014)
Comprehensive Mutation Analysis of the TERT Promoter in Bladder Cancer and Detection of Mutations in Voided Urine
Carolyn D. Hurst et al.
EUROPEAN UROLOGY (2014)
Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time
Guillaume Ploussard et al.
EUROPEAN UROLOGY (2014)
The Health Economics of Bladder Cancer: An Updated Review of the Published Literature
Christina Yeung et al.
PHARMACOECONOMICS (2014)
Urine markers for detection and surveillance of bladder cancer
Evanguelos Xylinas et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
Telomerase promoter mutations in cancer: an emerging molecular biomarker?
Joao Vinagre et al.
VIRCHOWS ARCHIV (2014)
Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder
E. Xylinas et al.
BRITISH JOURNAL OF CANCER (2013)
Evaluation of UroVysion and Cytology for Bladder Cancer Detection
Haythem Dimashkieh et al.
CANCER CYTOPATHOLOGY (2013)
TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine
Isaac Kinde et al.
CANCER RESEARCH (2013)
Maintenance Bacillus Calmette-Guerin Treatment of Non-muscle-invasive Bladder Cancer: A Critical Evaluation of the Evidence
Behfar Ehdaie et al.
EUROPEAN UROLOGY (2013)
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Maximilian Burger et al.
EUROPEAN UROLOGY (2013)
TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism
P. Sivaramakrishna Rachakonda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
The value of the NMP22 test for superficial bladder cancer diagnosis and follow-up
Caner Dogan et al.
TURKISH JOURNAL OF UROLOGY (2013)
Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic
Christopher G. T. Blick et al.
BJU INTERNATIONAL (2012)
Markers Predicting Response to Bacillus Calmette-Guerin Immunotherapy in High-Risk Bladder Cancer Patients: A Systematic Review
Tahlita C. M. Zuiverloon et al.
EUROPEAN UROLOGY (2012)
A Multigene Urine Test for the Detection and Stratification of Bladder Cancer in Patients Presenting with Hematuria
Paul O'Sullivan et al.
JOURNAL OF UROLOGY (2012)
Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?
George J. Netto
NATURE REVIEWS UROLOGY (2012)
Intravesical gemcitabine for non-muscle invasive bladder cancer
Gabriel Jones et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity
Ashish M. Kamat et al.
BJU INTERNATIONAL (2011)
FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy
Lucie C. Kompier et al.
PLOS ONE (2010)
A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer
Merle Hanke et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2010)
Quality of Pathologic Response and Surgery Correlate With Survival for Patients With Completely Resected Bladder Cancer After Neoadjuvant Chemotherapy
Guru Sonpavde et al.
CANCER (2009)
An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer
Per-Uno Malmstrom et al.
EUROPEAN UROLOGY (2009)
The role of BTA stat Test in follow-up of patients with bladder cancer:: results from FinnBladder studies
Mika-P. Raitanen
WORLD JOURNAL OF UROLOGY (2008)
Urinary NMP22® BladderChek® test in the diagnosis of superficial bladder cancer
PMJ Moonen et al.
EUROPEAN UROLOGY (2005)
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
AH Jebar et al.
ONCOGENE (2005)
Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer:: Formal meta-analysis of comparative studies on tumor progression
A Böhle et al.
UROLOGY (2004)
Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials
MD Shelley et al.
BJU INTERNATIONAL (2004)
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer
HB Grossman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Do prognostic parameters of remission versus relapse after bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature
F Saint et al.
EUROPEAN UROLOGY (2003)
Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity
A Bohle et al.
JOURNAL OF UROLOGY (2003)
The diagnostic odds ratio: a single indicator of test performance
AS Glas et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2003)
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials
RJ Sylvester et al.
JOURNAL OF UROLOGY (2002)
Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors
C Billerey et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Usefulness of the BTA stat Test for the diagnosis of bladder cancer
JLG Baños et al.
UROLOGY (2001)
Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients
JP Stein et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
